newsfilter
← Latest News
GlobeNewswire·

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of